Raffi Rembrand, who has an autistic son, has invented the SensPD, which detects a newborn suffering from sensory overload – a key factor in autism; The US FDA has approved the EluNIR medicated stent developed by Israel’s Medinol for the treatment of blocked or narrow coronary arteries; Sarah, a new Emergency Medical Technician with United Hatzalah – saved her own life, and much more.

ISRAEL’S MEDICAL ACHIEVEMENTS

Diagnosing autism in newborns

I reported previously (16th Apr) how Israel saves lives with early diagnosis of autism in toddlers. Now an Israeli, Raffi Rembrand, father of an autistic son, has invented the SensPD which detects a newborn suffering from sensory overload – a key factor in autism.

https://www.israel21c.org/israeli-dad-shows-how-newborns-can-be-screened-for-autism/

http://www.senspd.com/

US approval for medicated stent

The US FDA has approved the EluNIR medicated stent developed by Israel’s Medinol for the treatment of blocked or narrow coronary arteries. The stent system has a novel metallic spring tip and the narrowest strut width of any stent on the US market, for use in complex anatomy and disease.

https://www.globes.co.il/en/article-fda-approves-medinols-drug-coated-stent-1001214233

Newly trained EMT saves her own life

Sarah – a new Emergency Medical Technician with United Hatzalah – saved her own life when she managed to convince medics at her local hospital that she was suffering from a pulmonary embolism. When cynical hospital staff finally agreed to do a CT-scan, they found a clot in her lung.

http://www.israelnationalnews.com/News/News.aspx/238315

GE to use Israeli tech in ultrasound scanning

In my last newsletter (26th Nov) I reported that GE Medical are integrating the stroke diagnosis systems of Israel’s MedyMatch into its CT-scanners. This week, GE announced they will integrate the imaging analysis software from Israel’s DiA into its ultrasound devices.

https://www.timesofisrael.com/israels-dia-hopes-imaging-software-will-shake-up-ultrasound-use/

Heart-winning devices

Two Israeli startups were among the three finalists in the Cardiovascular Research Foundation’s Shark Tank Innovation competition held at the 2017 TCT Conference in Denver, Colorado. Enopace won, with its left ventricular neurostimulator (see here). Paragate’s fluid removal device came third.

https://www.israel21c.org/israeli-cardiac-devices-dominate-shark-tank-contest-wins/

Success for no-needle glucose meter

I reported previously (Sep 2013) about the non-invasive diabetes finger monitor TensorTip from Israel’s Cnoga.  The device uses skin color via LEDs to measure glucose levels and has received approval in Europe (CE certification), China and Brazil. It anticipates US FDA approval in 2018.

https://www.timesofisrael.com/israeli-device-banishes-finger-pricking-for-sugar-levels-in-diabetes-patients/

Saving patients with smart breathing tubes

Israeli-founded startup ART Medical has developed sensor-based smart tubes to monitor ICU patients on intubation, intravenous feeding and catheters.  They can detect and alert nurses and physicians of pneumonia or any abnormalities with gastric reflux, saliva, urine output etc.

https://www.timesofisrael.com/israeli-startup-creates-sensor-based-tubes-for-better-patient-monitoring/

http://www.globes.co.il/en/article-art-medical-seeks-to-make-hospitals-safer-1001191870

Personalized cancer treatment

I reported previously (many times) on Israeli companies developing cancer treatments targeting individuals rather than specific areas of the body. Now, Israeli biotech Ayala is partnering with Bristol-Myers Squibb to develop treatments for cancer patients known to have a gene mutation.

http://www.globes.co.il/en/article-nacht-harel-insurance-invest-in-personalized-cancer-treatment-1001214864

To read this week’s Good News from Israel, click HERE.